IQV vs MEDP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: IQV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IQV and MEDP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IQV and MEDP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). It operates in three segments: Technology & Analytics Solutions, which sells prescription and market data, real-world evidence, and commercial software to drug and device makers; Research & Development Solutions, its clinical research organization arm that designs and runs clinical trials on behalf of pharma and biotech sponsors; and Contract Sales & Medical Solutions. IQVIA makes money from long-duration trial contracts, recurring data and software subscriptions, and consulting, serving essentially all of the top 20 global pharmaceutical companies.

Full IQV guide

Medpace Holdings is a full-service, global clinical contract research organization that designs and runs Phase I through Phase IV clinical trials for biotechnology, pharmaceutical, and medical device companies. The business is deliberately concentrated on small and mid-sized biotech sponsors and complex therapeutic areas, and it employs roughly 6,300 people across more than 40 countries. Unlike larger peers that grow heavily through acquisition, Medpace has scaled organically, which has helped it post unusually strong margins and returns on capital for the sector.

Full MEDP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IQV drivers: Record backlog and bookings momentum; Proprietary data and analytics moat.
• MEDP drivers: Biotech-focused organic model; Backlog conversion engine.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: IQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. For MEDP, the biggest near-term concern is booking softness: net book-to-bill fell to roughly 0.88 in Q1 2026 as cancellations hit a multi-quarter high, which can slow future revenue if it persists.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IQV if you believe its drivers more; MEDP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IQV and MEDP guides.

IQV. IQVIA reported full-year 2025 revenue of about $16.3 billion with adjusted diluted EPS near $11.92, and issued 2026 revenue guidance of roughly $17.15 to $17.35 billion alongside adjusted EPS guidance of about $12.55 to $12.85. At a mid-2026 share price near $208 and a market cap around $35 billion, the stock traded at a P/E in the high teens to about 20x, a valuation that has compressed from prior years. The record backlog of about $34.2 billion provides visibility, but the pace of backlog-to-revenue conversion and biotech funding trends drive how much of that guidance is realized.

MEDP. Medpace beat on earnings but the stock fell sharply after Q1 2026 as net book-to-bill dropped below 1.0 and cancellations rose. Shares had already declined roughly a third from their 52-week high (near $629) toward the low $400s amid AI-disruption fears. The forward multiple has compressed from higher pre-selloff levels while the company still guides to high-single to low-double-digit revenue growth.

Headline figures (approximate, JULY 2026): IQV shows revenue (fy2025) ~$16.3 billion, adjusted diluted eps (fy2025) ~$11.92, adjusted ebitda (fy2025) ~$3.8 billion, backlog (q1 2026) ~$34.2 billion; MEDP shows q1 2026 revenue ~$707M (up ~26.5% YoY), q1 2026 diluted eps ~$4.28, 2026 revenue guidance ~$2.76-2.86B, 2026 eps guidance ~$16.68-17.50.

IQV and MEDP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IQV and MEDP exposure against your real portfolio. It is not an investment adviser.